Drug Trial Radar · NCT00602472
BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Mar 28, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,058
Actual
Start
Feb 2008
Primary completion
May 2009
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jan 28, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5 mg once daily) compared to placebo given for 24 weeks as add-on therapy to metformin in combination with a sulphonylurea in patients with type 2 diabetes mellitus with insufficient glycaemic control.
Conditions
- Diabetes Mellitus, Type 2
Interventions
linagliptinDrug
active
placeboDrug
placebo to linagliptin 5 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- HbA1c Change From Baseline to Week 24Time frame: Baseline and week 24
Locations
100 sites in 11 countries. Site status is shown where the registry gives one.
1218.18.54001 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
1218.18.54002 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
1218.18.54004 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
1218.18.54005 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
1218.18.54010 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
1218.18.54009 Boehringer Ingelheim Investigational Site
Córdoba, Argentina
1218.18.54013 Boehringer Ingelheim Investigational Site
Córdoba, Argentina
1218.18.54014 Boehringer Ingelheim Investigational Site
Corrientes, Argentina
1218.18.54003 Boehringer Ingelheim Investigational Site
Mar del Plata, Argentina
1218.18.54012 Boehringer Ingelheim Investigational Site
Mar del Plata, Argentina
1218.18.54011 Boehringer Ingelheim Investigational Site
Mendoza, Argentina
1218.18.54015 Boehringer Ingelheim Investigational Site
Parque Velez Sarfield, Argentina
1218.18.54006 Boehringer Ingelheim Investigational Site
Rosario, Argentina
1218.18.54007 Boehringer Ingelheim Investigational Site
Salta, Argentina
1218.18.32005 Boehringer Ingelheim Investigational Site
Bruges, Belgium
1218.18.32007 Boehringer Ingelheim Investigational Site
Brussels, Belgium
1218.18.32006 Boehringer Ingelheim Investigational Site
Edegem, Belgium
1218.18.32004 Boehringer Ingelheim Investigational Site
Genk, Belgium
1218.18.32003 Boehringer Ingelheim Investigational Site
Ghent, Belgium
1218.18.32002 Boehringer Ingelheim Investigational Site
Huy, Belgium
1218.18.32001 Boehringer Ingelheim Investigational Site
Liège, Belgium
1218.18.01005 Boehringer Ingelheim Investigational Site
Calgary, Alberta, Canada
1218.18.01010 Boehringer Ingelheim Investigational Site
Calgary, Alberta, Canada
1218.18.01003 Boehringer Ingelheim Investigational Site
Vancouver, British Columbia, Canada
1218.18.01011 Boehringer Ingelheim Investigational Site
Vancouver, British Columbia, Canada
1218.18.01006 Boehringer Ingelheim Investigational Site
Etobicoke, Ontario, Canada
1218.18.01009 Boehringer Ingelheim Investigational Site
Hamilton, Ontario, Canada
1218.18.01002 Boehringer Ingelheim Investigational Site
London, Ontario, Canada
1218.18.01012 Boehringer Ingelheim Investigational Site
Oakville, Ontario, Canada
1218.18.01008 Boehringer Ingelheim Investigational Site
Sarnia, Ontario, Canada
1218.18.01001 Boehringer Ingelheim Investigational Site
Toronto, Ontario, Canada
1218.18.01004 Boehringer Ingelheim Investigational Site
Montague, Prince Edward Island, Canada
1218.18.01007 Boehringer Ingelheim Investigational Site
Saskatoon, Saskatchewan, Canada
1218.18.86001 Boehringer Ingelheim Investigational Site
Beijing, China
1218.18.86002 Boehringer Ingelheim Investigational Site
Beijing, China
1218.18.86004 Boehringer Ingelheim Investigational Site
Beijing, China
1218.18.86013 Boehringer Ingelheim Investigational Site
Chengdu, Sichuan Province, China
1218.18.86009 Boehringer Ingelheim Investigational Site
Dalian, China
1218.18.86011 Boehringer Ingelheim Investigational Site
Guangzhou, China
1218.18.86014 Boehringer Ingelheim Investigational Site
Haerbin, China
Showing 40 of 100 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.